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Unification of de novo and acquired ibrutinib
resistance in mantle cell lymphoma
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Lancia Darville5, Ling Zhang1,4, Ying Han10, Dmitri Rebatchouk11, Maurizio Di Liberto12, Lynn C. Moscinski4,
John M. Koomen1, William S. Dalton3, Kenneth H. Shain1,3, Michael Wang6, Eduardo Sotomayor13,**
& Jianguo Tao1,3,4,**
The novel Bruton’s tyrosine kinase inhibitor ibrutinib has demonstrated high response rates in
B-cell lymphomas; however, a growing number of ibrutinib-treated patients relapse with
resistance and fulminant progression. Using chemical proteomics and an organotypic
cell-based drug screening assay, we determine the functional role of the tumour micro-
environment (TME) in ibrutinib activity and acquired ibrutinib resistance. We demonstrate
that MCL cells develop ibrutinib resistance through evolutionary processes driven by dynamic
feedback between MCL cells and TME, leading to kinome adaptive reprogramming, bypassing
the effect of ibrutinib and reciprocal activation of PI3K-AKT-mTOR and integrin-b1 signalling.
Combinatorial disruption of B-cell receptor signalling and PI3K-AKT-mTOR axis leads to
release of MCL cells from TME, reversal of drug resistance and enhanced anti-MCL activity in
MCL patient samples and patient-derived xenograft models. This study unifies TME-mediated
de novo and acquired drug resistance mechanisms and provides a novel combination
therapeutic strategy against MCL and other B-cell malignancies.
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M
antle cell lymphoma (MCL) is an aggressive B-cell
lymphoma that accounts for B6–8% of all B-cell
lymphomas. Prognosis remains poor in MCL patients
due to the emergence of drug resistance and lymphoma
progression1. MCL depends on the strong interactions between
lymphoma cells and their tumour microenvironment (TME)2,3.
Integrin b1-containing receptors (a4b1 and a5b1) are highly
expressed in MCL cells and are major mediators of cell adhesion to
stroma, provide protection against drug-induced apoptosis, and
confer environment-mediated drug resistance (EMDR)3. Recently,
the B-cell receptor (BCR) has emerged as a pivotal pathway in
many B-cell lymphomas4,5. Upon activation of BCR, CD79 is
phosphorylated, triggering a signalling cascade that involves
activation of kinases, GTPases and transcription factors
via a number of downstream pathways such as Bruton’s tyrosine
kinase (BTK), PI3K-AKT, ERK and NF-kB, promoting
lymphomagenesis6. Inhibitors of BCR signalling have emerged as
promising therapeutic agents for various B-cell lymphomas7–9.
Ibrutinib is a novel BTK inhibitor that has shown an
unprecedented overall response rate and progression-free survival
in relapsed/refractory MCL patients and in patients with other
B-cell disorders10,11. Clinically, ibrutinib rapidly induces
lymphocytosis and lymph node shrinkage, a phenomenon
common to BCR inhibitors, likely attributed to attenuation of
BCR-dependent lymphoma–TME interactions12–15. Unfortunately,
despite the dramatic responses to ibrutinib, resistance inevitably
develops. Approximately 43% of MCL patients have shown
partial or complete lack of response to ibrutinib and experienced
disease progression within 12 months of treatment. Alarmingly,
once patients relapse after ibrutinib treatment, the 1-year survival
rate is only 22% (refs 16,17). Similar outcomes have been
reported in patients with chronic lymphocytic leukaemia
after ibrutinib discontinuation because of disease progression
and drug resistance18.
Drug resistance is generally considered to evolve by intrinsic
or acquired genetic alterations and is heavily influenced by
the extrinsic TME3. TME-mediated resistance is a form of
de novo drug resistance that protects tumour cells from the effects
of diverse therapies. Acquired resistance to kinase inhibitors
is common and complex, involving mutations, reprogramming
and reactivation of key intracellular signal networks19,20.
However, the manner in which the TME contributes to
the development of acquired ibrutinib resistance (IR) is largely
unknown. To capture the complexity of IR, we applied activity-
based protein profiling (ABPP) to examine the kinome response
profiles in MCL modulated by stroma and/or chronic ibrutinib
treatment. We interrogated TME-mediated and acquired drug
resistance to determine the mechanistic link between TME and
acquired IR. Combining kinomics, longitudinal drug screening
with ex vivo, in vivo TME, and patient-derived xenograft (PDX)
models, we identified a major kinase network involving
PI3K-AKT-mTOR/integrin b1-integrin-linked kinase (ILK) as
a central hub for TME–lymphoma interactions mediating IR.
We found that combined disruption of BCR signalling and
central pathways resulting from kinome reprogramming is
critical for overcoming IR in MCL.
Results
BCR signal in TME–lymphoma interactions and drug resistance.
We investigated the role of BCR signalling in stroma-mediated
MCL cell survival and drug resistance and used a co-culture
model to evaluate the impact of stromal cells on phosphorylation
status of the BCR downstream proteins CD79a, BTK, ERK and
AKT. As shown in Fig. 1a,b, co-culture of MCL cells with
lymph node stromal cells (HK cells) or bone marrow stromal
cells (HS-5) significantly increased pBTK, pERK and pAKT in
MCL cell lines (HBL-2 and Jeko-1) and primary MCL cells.
Consistent with BCR activation, stroma-induced phosphorylation
of CD79a was observed (Fig. 1c). When CD79a was depleted
by using shRNA, stroma-induced activation of BTK and AKT
was abolished (Supplementary Fig. 1a), supporting that
BCR is required for stroma-induced activation of BTK, ERK
and AKT.
Next, we used selective BTK and PI3Kd inhibitors
(ibrutinib and GS-1101, respectively) to explore the functional
role of BCR signalling in MCL survival and stroma-mediated
drug resistance. Indeed, both ibrutinib and GS-1101 abolished
intrinsic and stroma-induced activation of BTK, AKT and
ERK (Fig. 1d, Supplementary Fig. 1b). Ibrutinib induced cell
apoptosis, sensitized responses to the cytotoxic agents and
suppressed MCL survival and clonogenic growth with
and without stroma co-culture. In addition, BCR signalling
pathway inhibition overcame stroma-mediated drug resistance
(Fig. 1e,f, Supplementary Fig. 1c,d). These data indicate
that TME/stroma trigger a sustained ‘outside-in’ BTK, ERK and
AKT activation via a stroma-induced BCR signal and with
enhanced MCL survival/drug resistance.
BCR activation in the context of stroma may be secondary
to a number of factors. To address how BCR is activated after
co-culturing with stroma cells, we evaluated whether stroma-
secreted proteins regulate BCR activation in MCL. LC-MS/MS-
based label-free proteomics experiments were performed to
quantify the secreted proteins (secretome) in HK cells. We
detected many cytokines (IL3, IL8, IL10, CCL3, CCL4), growth
factors (TGF-b, VEGF, HDGF, IGF2, PDGF) and extracellular
matrix proteins (fibronectin, collagen, MMP1/3, laminin) in the
supernatant of stromal HK cells. We identified 187 proteins in
the HK cell culture supernatant. By gene enrichment analysis,
the most enriched and shared proteins in the HK supernatant
were extracellular matrix proteins and adhesion/chemokine
molecules (Supplementary Fig. 1e).
Given that fibronectin binds to integrin b1 (b1) at the
cell surface and relays protective environmental signals to
cells, we examined changes in BCR signalling after MCL cells
were adhered to fibronectin-coated plates. Indeed, MCL cell
(Jeko-1, HBL-2) adhesion to fibronectin triggered a rapid
induction of BCR signalling activation manifested by increased
phosphorylation of CD79a, BTK, AKT and ERK (Supplementary
Fig. 1f). Because our previous work revealed that lymphoma
stroma-derived B-cell activating factor (BAFF) confers stroma-
mediated protection of MCL cells from therapy-induced
apoptosis21, we examined whether BAFF also activates the
BCR pathway. Addition of BAFF to MCL cell lines and to
primary B lymphocytes induced CD79a, BTK, ERK and AKT
phosphorylation. More importantly, neutralization of BAFF with
soluble TACI attenuated stroma-induced BCR activation
(Supplementary Fig. 1g), indicating that BAFF-like fibronectin
may contribute to stroma-induced BCR activation. Collectively,
these data indicate that BCR activation by stroma is multifactorial
and are in line with previous studies demonstrating that BCR and
its downstream proteins are activated by a variety of molecules,
including BAFF, antigen receptors and integrins22–24.
We also explored the contribution of BCR signalling to
b1 expression and MCL adhesion by co-culturing with HK or
HS-5 stroma cells. Co-culture with HK or HS-5 cells and
treatment with BAFF upregulated b1expression in MCL cells
(Fig. 1g, Supplementary Fig. 1h). As shown in Fig. 1h,i, targeting
BCR signalling with ibrutinib or GS-1101 blocked stroma-
induced b1 expression and attenuated MCL adhesion to stroma
in both MCL cell lines and primary MCL cells. We also found
that inhibition of AKT significantly decreased b1 expression
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and MCL cell adhesion to stroma, otherwise constitutively
AKT activation through myristoylated AKT plasmid (myr-Akt)
transfection increased expression of b1 and cell adhesion in these
MCL cells (Supplementary Fig. 1i,j). Thus, the PI3K-AKT
signalling pathway is a central ‘outside-in’ and ‘inside-out’
signalling hub for stroma–lymphoma interactions and stroma-
mediated drug resistance.
Adaptive kinome reprogramming in acquired IR MCL. To
investigate the IR mechanisms, we generated three independent
IR MCL cell lines by growing Jeko-1, HBL-2 and SP49 cells in
increasing concentrations of ibrutinib over 6 months
(Supplementary Fig. 2a). First, Sanger sequencing for the C481S
and R665W mutations in BTK and PLCG2 was performed in
these three pairs of MCL lines respectively. Intriguingly, no
pBTK
HBL-2
HBL-2 HBL-2 Jeko-1
HBL-2 +HK +HK +HKJeko-1 Mino
Ibrutinib
GS-1101
Integrin β1
HK-Ad HK-Ad
HBL-2
Su
s
H
S-
5 
6 
h
Su
s
H
S-
5 
6 
h
Jeko-1
75
75
50
50
37
37
75 100
Suspension HK-Ad
*
*
*
*
HS-5-Ad
DMSO Ibrutinib (2 μM)
R
el
at
iv
e
co
lo
ni
es
 (%
)
80
60
40
20
0
HB
L-2
0 0.5 1 3 6
Co-culture time
0 0.5 1 3 6
Co-culture time
Je
ko
-1
HB
L-2
Je
ko
-1
HB
L-2
Je
ko
-1
75
50
50
50
50
150
50
37
37
75
75
50
50
37
37
Jeko-1
0 15’ 30’ 3 h 6 h 12 h
0 15’ 30’ 3 h 6 h 12 h 24 h
0 15’ 30’ 3 h 6 h 12 h
BTK
pAKT
pERK
ERK
H K
pBTK
pAKT
pERK
pCD79a
pCD79a (green)
HK
CD79a
HBL-2
SP49
Ibrutinib –
–
–
– –
– –
–
–
–
–
–
+
–
–
––
– + –
+ –
–
––
– + –
+ –
–
––
– + –
+
150
50
+
+
+
+
++
+
GS-1101
pAKT 50
50
37
37
Jeko-1
DMSO GS-1101 Ibrutinib
MCL Pt
Jeko-1HBL-2
Ap
op
to
ltic
 c
el
ls 
(%
)
Ap
op
to
ltic
 c
el
ls 
(%
)
100
80
60
40
20
0
Ap
op
to
ltic
 c
el
ls 
(%
)
100
80
60
40
20
0 Ap
op
to
ltic
 c
el
ls 
(%
)
100
80
60
40
20
0
Sus SusHK-Ad
Sus HK-Ad Sus HK-Ad
HK-Ad
Ca
lce
in
 A
M
in
te
ns
ity
 (%
) 120 Adhesion to HK Adhesion to HK
Ibrutinib (μM) 0 1 10
100
80
60
40
20
0
100
80
60
40
20
0
** ** ** **
*
*
*
*
pERK
ERK
DMSO
Ibrutinib
Doxorubicin
Ibrutinib+Doxorubicin
AKT
+HK +HKMino
10 μm 10 μm
HBL-2+HK
DAPI (blue)
ERK
AKT
BTK
MCL1 MCL2 MCL3
Co-culture time
MCL4 MCL5
+–+–+–+–+–
AKT
pBTK
BTK
pAKT
pERK
ERK
AKT
*
*
HK
Integrin β1
α-tubulin
α-tubulin
Mino SP49
**
** **
**
*
*
*
*
Jeko-1HBL-2
Ca
lce
in
 A
M
in
te
ns
ity
 (%
) 120100
80
60
40
20
0
Jeko-1HBL-2
a
b
c
d
e
f
g
h
i
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms14920 ARTICLE
NATURE COMMUNICATIONS | 8:14920 | DOI: 10.1038/ncomms14920 |www.nature.com/naturecommunications 3
C481S and R665W mutations in BTK and PLCG2 reported in
IR chronic lymphocytic leukaemia were detected in all
lines19,20,25,26. Next, we determined the key signalling adaptations
associated with the development of acquired IR by performing
ABPP to identify global kinome in both parental and IR cells. For
ABPP, we used a desthiobiotin-ATP probe for selective labelling
of active sites in ATP-binding proteins, which was followed by
identification and quantification using liquid chromatography-
tandem mass spectrometry (Fig. 2a). By using three paired
parental and IR MCL cell lines, this approach identified
7,382 peptides corresponding to 2,327 ATP binding proteins,
including 547 peptides corresponded to 250 protein kinases
(Supplementary Fig. 2b). By extrapolating kinase expression in
gene profiling data from the published data (GSE34602,
GSE52148, GSE52434, GSE68091) in MCL lines (Jeko-1, HBL-2
and SP49), we concluded that there are 424 kinases present in
MCL cells. Thus, the 250 kinases identified by our proteomic
analysis accounted for approximately 59% of the expressed
kinome of MCL cells (Supplementary Data 1).
Next, by comparing changes in relative kinase activities
between IR and parental MCL cells at a system level, ABPP
revealed that the kinome of IR cells was markedly changed,
with many kinases displaying enhanced ATP probe binding in at
least two cell lines, indicating increased activity relative to
sensitive cells (Fig. 2b). These changes included biologically
significant protein kinases such as CDKs, ILK, DNA damage
response proteins and JAK-STAT kinases. By plotting the
frequency distribution of the kinase changes and dividing
the data into four quantiles, we selected fold changes of 1.35
for HBL-2, 1.92 for Jeko-1 and 2.28 for SP49 cells as cut-off
values, as these values defined the top quantile changes within
each cell line, and a significant overlap among these top quantile
kinases was observed (Supplementary Fig. 2c,d). Further mapping
of the overlapped kinases by using KEGG pathway analysis
identified PI3K-AKT-mTOR pathways as a central signalling
hub in IR MCL cells (Fig. 2c).
We next compared kinome alterations in sensitive and
IR cells following ibrutinib treatment and determined the
kinases/pathways that were inhibited with ibrutinib treatment
in sensitive cells but remained unaltered or elevated in IR cells
despite ibrutinib treatment. As illustrated in Fig. 2d, parental
cells were responsive to ibrutinib, showing reduction of
BTK binding in all three cell lines. We identified a kinome
signature with significant changes in ATP binding after
6-h ibrutinib treatment. The changes in protein kinase activity
by ibrutinib treatment could be attributed to both direct
and indirect ibrutinib targets. As expected, IR cells displayed
a more blunted response to ibrutinib than parental cells. Many
of the kinases demonstrated unchanged or even increased
activity in response to ibrutinib, supporting the concept that
BTK-independent kinases or BTK bypass pathways drive
IR (Fig. 2e and Supplementary Fig. 2e). Our analyses identified
40 kinases that remained unchanged or even elevated after
ibrutinib treatment, including multiple PI3K-AKT-mTOR-
related kinases (Fig. 2e). Because the PI3K-AKT-mTOR pathway
was most frequently found in this setting (Fig. 2c), we further
assessed activation of PI3K-AKT-mTOR and its downstream
targets in parental and IR MCL cells. Among these, we found
significantly increased AKT, 4EBP and S6K1 phosphorylation
levels in IR cell lines compared with their parental cells (Fig. 2f).
Ibrutinib effectively decreased AKT and BTK phosphorylation
in parental MCL cells. In contrast, high AKT phosphorylation
in IR MCL cell lines was sustained in the presence of ibrutinib
treatment, suggesting a mechanism of bypassing the effect
of ibrutinib to promote activation of the PI3K-AKT-mTOR axis.
PI3K-AKT-mTOR pathway activation in IR MCL cells.
We detected increased b1 expression in IR MCL cells compared
with parental lines (Fig. 3a,b). Moreover, flow cytometry showed
that b1 expression was further enhanced upon co-culture with
stroma (Supplementary Fig. 3a). After ibrutinib exposure,
b1 expression levels were reduced in parental/naı¨ve, although
levels remained unchanged after ibrutinib treatment in IR MCL
cells (Fig. 3a,b). Adhesion assays and clonogenic growth
experiments with and without ibrutinib treatment showed that
IR MCL cells had a marked increase in adhesion to stromal cells
and enhanced clonogenic growth in the presence of ibrutinib
(Fig. 3c,d and Supplementary Fig. 3b). Furthermore, stable
b1 knockdown dramatically attenuated cell adhesion to stromal
cells, cell survival and clonogenic growth in IR cells (Fig. 3e,f and
Supplementary Fig. 3c–e).
The interplay of persistent PI3K-AKT-mTORC activation and
b1 expression were evaluated to gain insight into the underlying
mechanism of PI3K-AKT-mTOR pathway activation in IR MCL
cells. Indeed, mTORC2 signalling and mTORC1 downstream
pS6K and p4EBP were significantly attenuated in stable
b1 knockdown IR cell lines (Fig. 3f). Because b1 signals have
been reported to be associated with ILK and ILK activation has
been consistently identified in IR cells by ABPP (Fig. 2b–f),
co-immunoprecipitation assay revealed that b1 immunoprecipi-
tated with ILK in IR cells (Fig. 3g,h). In contrast, no b1-ILK
complex formations were detected in b1 knockdown stable
Jeko-1-IR and HBL2-IR cells. We also probed for co-precipitated
ILK with rictor, an upstream activator of AKT activation, and
identified ILK-rictor complexes in Jeko-1-IR and HBL-2-IR cells
(Fig. 3h). These data indicate that b1 regulates mTORC2-AKT
pathway activation via ILK-rictor complex formation. We also
examined b1-ILK-rictor complex formation after ibrutinib
treatment and observed persistent b-ILK-rictor complexes in
Figure 1 | B-cell receptor (BCR) signalling is a central ‘outside-in’ and ‘inside-out’ signalling hub for MCL cell survival and growth. (a) Co-culture with
lymph node stromal cells (HK-Ad) and bone marrow stromal cells (HS-5) induced a time-dependent BCR signalling activation detected by western blot for
BCR downstream molecules (BTK, AKT, ERK) phosphorylation in MCL cell lines (HBL-2, Jeko-1). (b) Co-culture with lymph node stromal cells induced
BCR signalling activation detected by western blot for BCR downstream molecules (BTK, AKT, ERK) phosphorylation in primary MCL samples (MCL1–5).
(c) Co-culture with lymph node stromal cells induced BCR (CD79a) phosphorylation detected by western blot and immunofluorescence staining in
HBL-2 cells in co-culture with HK cells. Scale bar, 10mM. (d) Inhibition of BCR signalling using BTK and PI3Kd inhibitors (50 nM ibrutinib and 100 nM
GS-1101) attenuated stroma-induced AKT and ERK activation in SP49 and Mino cells. (e) Ibrutinib induced cell apoptosis, overcame stroma-mediated
drug resistance and enhanced doxorubicin (0.5mM)-induced apoptosis in Jeko-1, HBL-2, Mino and SP49 cells (Sus, cells in suspension, HK-Ad, cells
in co-culture with HK cells). *Po0.05 and **P40.05 (Student’s t-test). (f) Ibrutinib inhibited clonogenic growth with and without stroma co-culture. (g)
Co-culture of stromal HK cells with MCL cells upregulated b1 expression in HBL-2 and Jeko-1 cells. (h) Inhibition of BCR signalling using BTK and PI3Kd
inhibitors (1mM ibrutinib and 1mM GS-1101) attenuated stroma-induced integrin b1 expression in HBL-2, Jeko-1 and Mino cells. (i) Inhibition of BCR
signalling by ibrutinib attenuated adhesion of HBL-2, Jeko-1 and MCL patient cells to stroma cells (HK or HS-5) determined by microscopic examination and
by the intensity of calcein-AM. Results in a–i are representative or means±s.d. from at least three biological replicates. See also Supplementary Figs 1, 8 for
full gel scan of the WB.
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Figure 2 | Chronic ibrutinib treatment leads to kinome reprogramming and PI3K-AKT-mTOR pathway activation and ibrutinib resistance in MCL cells.
(a) Schematic workflow of activity-based protein profiling (ABPP) to identify global kinome changes in MCL cells. Briefly, cell lysis were sonicated, desalted
and followed by incubation with 10mM desthiobiotin-ATP probes. The labelled proteins were reduced, alkylated and trypsin digested, and the labelled
peptides were purified with high capacity streptavidin agarose resin, washed, eluted and subjected to LC-MS/MS for quantification. (b) Kinome profiling of
IR MCL cells compared with parental cells (HBL-2, Jeko-1, SP49). Ratios Z1 indicate increased kinase ATP probe binding with relative increased activity,
and valueso1 indicate decreased ATP probe binding with decreased activity relative to parental cells. Data averages of two biological replicates. (c) KEGG
pathway analysis map showing activation of PI3K-AKT-mTOR as a central signalling hub of kinome reprogramming for IR development. Pink, kinases with
increased activity detected by ABPP. (d) Common kinase ATP-binding changes after 6-h ibrutinib treatment in all three parental MCL cell lines (Jeko-1,
HBL-2, SP49). Kinome trees reproduced courtesy of Cell Signaling Technology. (e) Sustained kinase ATP-binding activity in IR MCL lines relative to their
parental cell lines after 6 h ibrutinib treatment. (f) Western blots showing increased AKT, 4EBP and S6K1 phosphorylation in Jeko-1-IR and HBL-2-IR cell
lines, as well as sustained AKTactivation in the presence of ibrutinib (6 mM, 12 h) treatment in IR cells compared with parental (Sen) cells. (b,d,e) are from
two biological replicates with four technical replicates. Results in f are representatives of three independent experiments. The relative changes of proteins
were measured by quantitative densitometry and indicated below each lane. See also Supplementary Figs 2, 8 for full gel scan of the WB.
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IR cells but not in their parental cells (Fig. 3i). Together, these
results demonstrate the reciprocal activation loop of PI3K-AKT-
mTOR and b1 signalling, a central signalling hub for IR, resulting
in enforced TME–lymphoma interactions and promoting
MCL growth and drug resistance.
Functional dissection of mTORC1 and mTORC2 in IR MCL cells.
To functionally define the distinct role of mTORC1 and/or
mTORC2 in MCL growth and cell adhesion to TME stroma, we
used the dual PI3K-mTOR1/2 inhibitor BEZ235 and the dual
mTOR1/2 inhibitor AZD8055. BEZ235 and AZD8055 decreased
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AKT phosphorylation, b1 expression and adhesion to stroma in
Jeko-1-IR and HBL-2-IR cells (Fig. 4a–c, Supplementary Fig. 4a).
BEZ235 induced G1 arrest in Jeko-1-IR and HBL-2-IR cells
(Supplementary Fig. 4b). In contrast, rapamycin, an allosteric
inhibitor of mTORC1, induced cell cycle G1 arrest, attenuated
activation of mTORC1 downstream proteins such as S6K1, but
had no effect on AKT activation, b1 expression or cell adhesion
(Fig. 4d and Supplementary Fig. 4c). Consistent with these data,
we observed that blocking mTORC2 by rictor knockdown
using siRNAs decreased b1 and pAKT levels and decreased cell
adhesion. However, blocking mTORC1 by raptor knockdown
using siRNAs showed no changes in b1 expression and cell
adhesion (Fig. 4e,f, Supplementary Fig. 4d). In line with
these data, inhibition of AKT attenuated b1 expression and cell
adhesion (Fig. 4g, Supplementary Fig. 4e,f). Collectively, the
functional regulation of the PI3K-AKT-mTORC1 pathway
is essential for cell growth and the mTORC2-AKT pathway
contributes to b1 expression, adhesion and proliferation in
IR MCL cells (summarized in Fig. 4h).
Unification of TME-mediated and acquired IR in MCL. With
our demonstration that IR correlated with increased b1 expres-
sion, we anticipated that this would lead to a greater potential for
IR cells to interact with TME compared with naı¨ve cells in the
presence of ibrutinib. Using the three naı¨ve/IR cell line pairs, we
sought to address the question of how cell adhesion influences
acquired drug resistance. We elucidated kinome network of
(1) de novo (TME-mediated), (2) acquired drug resistance and
(3) IR selected while adherent to TME stroma (combined IR)
(Fig. 5a). Our ABPP analysis detected 220 kinases, including
24 kinases with more ATP binding than when these cells were
adhered to stromal HK cells (Fig. 5b). In addition, we performed
and compared the HK-induced kinome alteration with bone
marrow stroma HS-5-induced kinome changes and found
significant overlap between these two conditions in all three cell
lines (Supplementary Fig. 5a), supporting that HK and HS-5
mediated common kinase signalling at least to some degree.
Furthermore, acquired IR was associated with 205 kinase altera-
tions, including 40 kinases with greater ATP binding (Fig. 5b).
IR selected in the presence of stroma designated as IR-TME
(Fig. 5b) demonstrated 210 kinases, including 33 with greater
ATP binding (Fig. 5b, right). Integrated principal component
analysis showed that all three types of drug resistance clustered,
respectively, and distant from parental cells, and combined
IR shared kinase signature with both de novo and acquired
IR (Fig. 5c, Supplementary Fig. 5b). With further pathway
analysis by KEGG, we found that all three conditions demon-
strated a greater overlap of kinome reprogramming and pathways
in IR and IR-TME relative to those of de novo TME-mediated
drug resistance (Fig. 5d, Supplementary Fig. 5b). Similar to
acquired IR cells, b1 and PI3K/AKT signalling were comparably
activated and maintained at higher levels after ibrutinib treatment
in these IR-TME cells (Supplementary Fig. 5c). We also observed
that these cells have increased growth potential, are more adhe-
sive and conferred more clonogenic growth (Supplementary
Fig. 5d–f) similar to that shown in IR phenotypes. Overall, these
data provide the biological significance of the kinome alterations,
and these two forms of resistance interact in a unified way to
initiate and amplify the drug resistant phenotypes.
Ibrutinib resistance in in vivo murine model and primary MCL.
We applied parental and IR MCL cells to in vivo xenograft
models to validate (1) whether TME stroma promotes tumour
progression in both parental and IR MCL cells, (2) whether
IR MCL cells conferred greater tumour-forming potential and
(3) whether PI3K-AKT-mTOR activation was sustained and
b1 was upregulated. Parental and IR HBL-2 cells with or without
HK stromal cells were subcutaneously injected into the lower
flank of NOD/SCID mice, and tumour volume was assessed.
Consistent with previous results, a more robust growth of
tumours was observed in mice receiving HK and HBL-2 cells than
in mice injected with HBL-2 cells alone2,27.
Given our previous demonstration that HK cells alone
could not induce lymphoma formation and that very small
to minimal amounts of HK cell were present even in co-injection-
induced lymphomas, we concluded that the robust growth
of tumours is attributed to MCL growth and proliferation2.
Importantly, compared with parental sensitive cells, the
MCL tumour volume derived from IR cells demonstrated
greater tumour volume both with and without concomitant
stromal cells (Fig. 6a), suggesting greater tumour-forming
potential. Mechanistically, western blot and flow cytometry
revealed higher b1 expression, AKT/4EBP phosphorylation
in xenografted MCL tumors from mice receiving HK and
HBL-2 cells and in xenografted MCL tumors in mice receiving
IR HBL-2 cells compared with those receiving HBL-2 cells only or
parental cells (Fig. 6b). Immunohistochemical staining of
primary ibrutinib-sensitive and IR patient MCL samples
revealed increased AKT activation and b1 expression in IR
MCL cells (Fig. 6c, Supplementary Fig. 6a). We observed
significantly increased b1 expression levels in six of seven IR
MCL samples, whereas only one of eight ibrutinib-sensitive MCL
samples revealed a moderate b1 staining. Moreover, two patient
samples that initially responded but ultimately progressed were
from biopsies at the time of initial diagnosis and at relapse on
ibrutinib treatment (Fig. 6c).
Next, we capitalized on a novel ex vivo organotypic live
imaging cell-based platform to assess drug response in parental
and IR cells in reconstructed TME28,29. In this system, MCL cells
(SP49) of parental and IR were seeded in a 384-well
plate previously coated with human-derived stroma cells and
collagen-1, and drug screen was performed using 31 agents,
Figure 3 | Interplay of PI3K-AKT-mTORC and integrin b1/integrin linked kinase pathways in IR MCL cells. (a,b) Western blots (a) and flow cytometry
(b) showing increased and sustained integrin b (b1) expression in IR MCL cells compared to parental (Sen) cells in the absence and presence of ibrutinib
treatment (6 h). (c) Cell adhesion assay showing increased and sustained cell adhesion of IR MCL cells to stromal HK cells in the absence and presence of
ibrutinib treatment (12 h). (d) Colony formation assay showing enhanced clonogenic growth in IR MCL cells in the absence and presence of ibrutinib
treatment. (e,f) Cell adhesion assay (e) and western blots (f) showing stable integrin b1 (CD29) knockdown with shRNAs significantly decreased
rictor, pAKT, p4EBP and pS6K1 in IR MCL cells and significantly attenuated cell adhesion of parental (Sen) and IR MCL cells to HK stromal cells.
(g) Co-immunoprecipitation revealed b1 and ILK form a complex in Jeko-1-IR and HBL-2-IR cells and b1 knockdown abolished b1/ILK complex formation.
*indicates the specific band for integrin b1 (h) Co-immunoprecipitation showing ILK co-immunoprecipitates with rictor to form a more abundant complex in
Jeko-1-IR and HBL-2-IR cells versus that shown in their parental (Sen) cells. (i) Co-immunoprecipitation showing suppression of b1/ILK co-immunoprecipite
formation in parental (Sen) but not in IR MCL cells after ibrutinib treatment in HBL-2-IR and Jeko-1-IR cells. Scale bar, 10 mm. Results in a–g are
representative of at least three independent experiments or means±s.d. from at least three biological replicates. For a–f, relative changes of proteins were
measured by quantitative densitometry and indicated below each lane. See also Supplementary Figs 3, 8 for full gel scan of the WB.
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Figure 4 | Functional dissection of mTORC1 and mTORC2 in cell growth and stroma/MCL interaction in acquired IR MCL cells. (a–c) Treatment with
the PI3K/mTOR inhibitors BEZ235 and AZD8055, but not ibrutinib, significantly decreased AKT phosphorylation, b1 expression (a,b), and adhesion to
HK stromal cells (c) in IR MCL cells. (d) Rapamycin inhibited mTORC1 activation, but had no effect on AKT activation and b1 expression in IR MCL cells.
(e,f) Inhibition of mTORC2 by rictor knockdown using a pool of siRNAs decreased AKT activation, b1 expression and cell adhesion. In contrast, blocking
mTOR1 by raptor knockdown with siRNA showed no changes in AKT activation and b1 expression in IR MCL cells. (g) Treatment with AKT inhibitor
(AKTi, A674563, for 12 h) significantly attenuated b1 (CD29) expression in IR MCL cells. (h) Diagram of functional regulation of mTORC1 and mTORC2 in
proliferation, AKT activation, b1 expression and cell adhesion in IR cells. Results in a–g are representative of at least three independent experiments or
means±s.d. from at least three biological replicates. See also Supplementary Figs 4, 8 for full gel scan of the WB.
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Figure 5 | Functional coordination between TME-mediated (de novo) and acquired IR. (a) Diagram of three types of drug resistance mechanisms for
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including protein kinase inhibitors, inhibitors of deacetylase,
proteasome inhibitors and chemotherapeutic agents. As shown in
Fig. 6d, IR cells conferred greater growth potential and became
more adherent compared with the parental cell line. Increased
viability in the presence of ibrutinib was also noted in IR cells.
Treatment with doxorubicin resulted in more viable IR cells
and/or stroma-mediated drug resistance. Critically, AKT and
mTOR inhibitors demonstrated more dramatic attenuations of
cell viability in IR cells versus naı¨ve cells, consistent with
our hypothesis that this pathway serves as a key compensatory
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mechanism in IR. Importantly, the ex vivo screen also
demonstrated that protein kinase inhibitors targeting JAK1,
JAK2, aurora A, IGF1R and PLK suppressed cell growth of
IR MCL cells (Fig. 6e). Of note, these pathways/kinases were
also identified through ABPP in IR MCL cells (Fig. 2); thus
a functional proof of principal for adaptive changes was observed
in IR cell kinome.
Novel therapeutics in murine and patient-derived xenografts.
To further validate the compensatory role of PI3K-AKT-mTOR
signalling in IR, we turned to the three pairs of parental and
IR MCL lines. When BEZ235 or AZD8055 was combined
with ibrutinib, cell survival, b1 expression, cell adhesion and
clonogenic growth were substantially inhibited in all IR MCL
lines and in patient samples of acquired IR MCL (Fig. 7a–c,
Supplementary Fig. 7a,b). As shown in Fig. 7c, AZD8055 or
AZD8055 plus ibrutinib, but not ibrutinib alone, induced
significant changes in cell adhesion to stroma in IR MCL samples.
Persistent b1 expression and cell adhesion to stroma despite
ibrutinib treatment were observed in these patient samples,
with BEZ235 and AZD8055 in combination with ibrutinib
more significantly reducing b1 expression, AKT activation and
cell adhesion to stroma (Fig. 7b,c, Supplementary Fig. 7c).
We further administered AZD8055 in NOD/SCID mouse for its
anti-lymphoma activity in combination with ibrutinib by using
HBL-2-IR MCL cells and HK stroma cells. As expected, HBL-2-
IR was resistant to ibrutinib treatment; however, AZD8055
induced remarkable inhibition of MCL growth and in combina-
tion with ibrutinib further suppressed lymphoma formation.
ADZ8055 in combination with ibrutinib markedly reduced
pAKT, pS6K1, p4EBP and b1 expression levels and reduced cell
adhesion to HK cells in these xenograft tumour cells (Fig. 7d,e,
Supplementary Fig. 7d).
To further examine our hypothesis, we used our previously
described MCL PDX model to test response of IR cell lines to
ibrutinib and combination treatment. As shown by Wang et al.30,
a SCID-hu mouse model developed for myeloma allowed
primary human MCL cells to be injected directly into the
microenvironment of human fetal bone in SCID mice. In the
SCID-hu mice, the bone implants vascularized and were
histologically similar to bone marrow, providing a TME for
tumour growth with lymphoma manifestations such as increased
serum human b2 microglobulin levels. We found that
NOD/SCID IL-2Rg (NSG) mice are a more suitable strain for
PDX propagation for first generation of PDXs in SCID-hu mice.
For this experiment, MCL cells isolated from an abdominal mass
of a 74-year-old female patient who progressed after ibrutinib
treatment were injected directly into the human fetal bone of
SCID mice. Four to eight weeks after inoculation, a large tumour
mass was observed around the implanted human bone, spleen
and abdominal lymph node. The PDXs established in the
SCID-hu model were then transferred from the SCID-hu mice
into NSG mice, and we randomly divided the mice bearing the
cells from the same patient into treatment groups (5 mice per
group). Histological examination, CD20 and cyclin D1 analyses,
and flow cytometry confirmed MCL diagnosis, with tumours
comparable to the original diagnosed MCL (Supplementary
Fig. 7e).
As shown in Fig. 7f, NSG mice bearing the PDXs were treated
with one of the following six conditions: vehicle, ibrutinib alone,
AZD8055 alone, BEZ235 alone, ibrutinib with AZD8055 and
ibrutinib with BEZ235 (all by daily oral gavage). Tumour
volume was assessed on days 1, 12 and 19 after treatment.
Consistent with the IR nature, the tumours in all mice treated
with single-agent ibrutinib grew rapidly despite drug treatment,
and tumour volumes were unchanged or even increased with
low-dose AZD8055 or BEZ235 alone compared with vehicle
(Fig. 7f). In contrast, tumour volumes were significantly
decreased in the two-drug combination groups of AZD8055 or
BEZ235 plus ibrutinib compared with control or ibrutinib
monotherapy (Fig. 7f).
Discussion
Acquired drug resistance has traditionally been studied by
chronically exposing cancer cell lines in vitro to increasing doses
of drug. These drug-resistant models have been instrumental in
identifying mechanisms that modulate drug response and, in
some cases, have aided in the identification of drug targets31.
However, these models have failed to account for the TME in
the emergence of the drug-resistant phenotype. Here, we combined
lymphoma TME models, using functional and chemical proteomics
approaches, to define the key protein kinase reprogramming
and a central signalling hub for TME-induced- and acquired
IR in MCL.
PI3K-AKT pathway activation has been identified as an
important drug resistance mechanism in many tumours. How-
ever, our study uniquely characterized the development of
acquired IR in the context of TME and unified TME-mediated
and acquired IR, providing a mechanistic link between TME and
acquired IR. Our data indicated that their interplay and
cooperative function are critical for promoting tumour growth,
IR and MCL progression. In addition, we identified integrin
b1-ILK signalling as the underlying mechanism of not only
PI3K-AKT activation in MCL IR but also TME in facilitating
Figure 6 | IR mechanism sustained in in vivo xenograft model, ex vivo primary MCL specimens and recapitulated in drug screening assay. (a) Xenograft
experiments showed that HK cells enhanced tumour formation of both parental (Sen) and IR MCL cells (HBL-2). IR MCL cells had more robust tumour
formation in vivo compared with parental cells. *Po0.05, n¼ 5 per cohort (Student’s t-test). (b) Immunoblot and flow cytometry conducted on MCL
samples from NOD/SCID mice injected with HBL-2 cells and IR HBL-2 with and without co-injection of HK cells of cohorts as described in a. 1–8 represent
eight xenografts, with relative expression of pAKT and p-4EBP were quantitated by quantitative densitometry and shown in coloured bar graph. (c)
Immunohistochemistry stains showing elevated AKT activation (c) and b1 expression (d) in IR MCL patient samples when compared with ibrutinib-
sensitive samples or samples on the progression after ibrutinib treatments. Scale bar, 10mm. (d) A cell-based drug screening assay was used to measure
cell growth and chemosensitivity to indicated chemical agents in a reconstructed TME. Parental and IR cells (SP49-Sen and SP49-IR) were seeded in 384-
well plates of reconstructed bone marrow, including high physiological cell densities (1–10 106 cells per ml), extracellular matrix (collagen 1) and human
bone marrow derived stromal cells (BMSC). A panel of drugs at five different concentrations was added to the media, and plates were continuously imaged
for 96 h using a digital image analysis algorithm to identify viable cells based on membrane motion (pseudo-coloured in green). Changes in viability are
quantified by area under curve (AUC). Left, cell growth and viability of sensitive (Sen) and IR MCL cells was measured with no treatment, treatment
with ibrutinib, doxorubicin, MK2206 or INK128; right, images at 48 h in these conditions. Negative controls (no drug) were included, as well as positive
controls for each drug (cell line MM1.S at highest drug concentration). Scale bar, 30mm. (e) Heat map showing chemosensitivity of parental (Sen) and IR
cells (Resis) to 31 agents including protein kinase inhibitors, inhibitors of enzymatic processes and chemotherapeutic agents. See also Supplementary
Figs 6, 8 for full gel scan of the WB.
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acquired IR resistance. More importantly, our functional and
chemical proteomic results were independently validated by
cell-based drug screen experiments in the setting of TME,
implicating this drug screen assay as an innovative platform to
help with design of effective individualized combination therapies
to overcome IR and disable aggressive lymphomas. A simplified
model showing the enforced interaction of the MCL-TME
and development of IR is illustrated in Fig. 7g. As shown here,
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the TME–lymphoma interaction allows MCL cells to survive
initial drug exposure and eventually acquire a complex array of
acquired drug resistance mechanisms through kinome
reprogramming.
We compared functional resistance mechanisms and
corresponding kinase activation profiles associated with de novo
TME-mediated and acquired resistance mechanisms. When
MCL cell lines selected in the absence of stroma for acquired
IR were compared with parental MCL cell lines after adhesion
(co-culture) to the stroma (de novo, EMDR), we found that
acquired IR mechanism was more complex than that of EMDR.
The complex changes in IR MCL cell kinome could contribute to
the observed phenotypic alterations. The kinomic changes
account for increased proliferation and drug resistance in
acquired resistant MCL cells, whereas activation of adhesion/
integrin b1 signalling pathways contributed to enhanced
TME–MCL cell interaction and amplified EMDR. Despite
differences in the models for acquired and de novo drug
resistance, we observed a significant overlap in kinase changes,
supporting that EMDR is essential for initial survival, priming
MCL cells for the acquisition of stable drug resistance. In line
with this, our in vivo xenograft model revealed that TME stroma
cells promote MCL growth and that IR MCL cells confer an
advantage in stroma interaction, drug resistance and clonogenic
growth ability. The adaptive kinome reprogramming and
potential targets were further evidenced by an independent
ex vivo drug screening that quantified drug sensitivity in
a reconstructed TME. Furthermore, when selecting IR to chronic
ibrutinib exposure in MCL cells adherent to stroma and
developing IR MCL lines in the setting of TME (IR-TME), we
observed that the kinome profile of cells from ‘combined
selection’ are more closely related to the cells with acquired
resistance than cells selected by de novo resistance in co-culture
with stroma. Comparable changes in b1-ILK expression,
PI3K-AKT-mTOR pathway activation, enhanced cell adhesion
and growth in MCL cells were detected with both conditions.
These results highlight that development of IR represents
a multiple stepwise process requiring a complex interplay
between TME signals, gene and protein adaptation, and
selection pressures, with ILK and PI3K-AKT-mTOR being
potential target for overcoming IR.
Initially, cell–cell or cell–TME interactions attract MCL cells to
the stromal niche, conferring MCL BCR signal for MCL survival.
When therapeutic stress was applied, a series of cell responses
occurred in both MCL cells and stromal cells, creating a positive
feedback loop that amplified the pro-survival and anti-apoptotic
signals, with eventual TME-independent acquired resistance
dominating the late stage, although TME still physically or
biochemically influenced the drug resistance phenotype.
Together, our data support that the drug-resistant population
presents a kinase activity pattern different from the one seen
in the original naı¨ve tumour. This is because de novo and/or
acquired drug resistance mechanisms may drive clonal evolution
before, during and after therapies.
Our results are consistent with the complex nature of resistance
mechanisms. Resistance is often ascribed to either resistant
mutations such as BTK and PLCg2 reported in IR MCL and
chronic lymphocytic leukaemia or adaptive mechanisms, includ-
ing amplification of alternative signalling pathways and altered
cell states19,20. Given the complex heterogeneous nature of
MCL and its TME, resistance to anti-cancer therapies probably
stems from pre-existing clonal heterogeneity and clonal
evolution, resulting from a combination of mutations or
alteration of genetic and epigenetic determinants as part of
adaptive responses to therapy and interplay with TME32–34. Our
data further highlight that tumour cell heterogeneity and clonal
evolution in response to the selective pressure of a toxic agent
usually prevents long-term efficacy of any monotherapy.
Advances in proteomics techniques have now allowed the
simultaneous quantification of several thousand proteins,
which can be used to derive signalling networks from large-
scale data sets35–37.
In our study, we used ABPP and defined a kinase signalling
network in parental and IR MCL cells and the adaptive rewiring
in response to ibrutinib in de novo TME and acquired
drug resistance. The remodelling of kinase networks in IR cells
produced patterns of signalling activity linked to their evolved
phenotypes. Given the myriad of therapeutic resistance mechan-
isms, including point mutations in known targets, network-wide
approaches are crucial to improving our understanding of altered
survival and drug resistance as a consequence of reprogramming
and ultimately determining the success or failure of therapeutic
agents. Thus, when considering the use of targeted therapies
in cancer, it is necessary to understand and integrate the multiple
tumour cell adaptation mechanisms to a given therapy to better
design a combination of therapies with optimal anti-tumour
effects. The identification of ‘common signalling nodes’ or drivers
for resistant clonal evolution in multiple altered signalling
pathways that confer resistance is warranted. Our findings
suggest a more complex network to stable genetically conferred
resistance to cancer drugs than the specific drug resistance
mutations. Such mutations could arise spontaneously at low
frequency before drug treatment and are selected during
treatment. However, our observations implicate a multistep
stepwise process mediated by TME and tumour interaction
is not incompatible with ‘pre-existing’ resistance-conferring
mutations. Because of the dynamics and complexity of tumour
evolution and often lack of correlation between mutations
with therapy response, our cell-based drug screen in the setting
of TME can provide a promising tool for effective individualized
Figure 7 | Inhibition of the PI3K-AKT-mTOR pathway overcomes IR in ex vivo and in vivo using patient derived xenografts (PDX) model.
(a–c) AZD8055 treatment in combination with ibrutinib more substantially inhibited cell viability measured by CCK8 assay in IR MCL cells (a), more
substantially inhibited b1 expression (b) in two IR primary samples and cell adhesion (c) in four IR primary MCL patient samples. *Po0.05 and **PZ0.05
(Student’s t-test). (d,e) AZD8055 treatment led to a reduction in tumour growth that was enhanced in combination with ibrutinib (co-treatment). (d) the
co-treatment of AZD8055 and ibrutinib markedly reduced pAKT, p4EBP and CD29 levels (e) in murine xenografts as indicated. (f) Combinatorial
treatments of BEZ235 or AZD8055 with ibrutinib induced more dramatic anti-MCL activity in a patient-derived xenograft from IR MCL (PDX). The NSG
mice bearing the PDXs were randomly divided into six groups (5 per group), with growing tumours subsequently treated with solvent (equal volume of
vehicle, blue), ibrutinib 25mg kg 1 alone (orange), AZD8055 5mg kg 1 alone (purple), BEZ235 10mg kg 1 alone (green), ibrutinib 25mg kg 1 with
AZD8055 5mg kg 1 (red), or ibrutinib 25mg kg 1 with BEZ235 10mg kg 1 (green) all by oral gavage daily. Tumour burden was assessed by tumour
volume measurements at days 1, 12 and 19 after treatment. (g) A simplified IR model showing enforced interaction of the MCL-stromal cells and IR
development under ibrutinib treatment. b1 contributed to the PI3K-AKT-mTOR1 activation through forming complex with ILK and mTORC2 and that
PI3K-AKT, in turn, induced b1 expression, thereby generating a positive feedback loop, ensuring high level and sustained TME–lymphoma interaction and
allowing cells to acquire a more permanent and complex drug resistance phenotype in MCL cells. Results in a,c are shown as meanþ s.d. from at least three
biological replicates. See also Supplementary Figs 7, 8 for full gel scan of the WB.
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therapy against MCL and other B-cell lymphomas. The continued
application of this approach in combination with genomes,
functional transcriptome and proteomes to primary and
recurrent tumours will identify novel mechanisms driving
tumour progression and therapeutic resistance, facilitating the
identification of optimal combinatorial therapeutic strategies.
The inhibition of these pathways and resistance networks
could be a more efficient way to overcome drug resistance
and improve current therapies for patients with MCL and other
B-cell malignancies.
Methods
Activity-based protein profiling. Briefly, cell pellets were sonicated in IP/lysis
buffer, desalted with Zeba spin desalting column and followed by incubation with
10mM desthiobiotin-ATP probes at room temperature for 10min. The labelled
proteins were reduced, alkylated and trypsin digested at 37 C for 2 h. The labelled
peptides were purified with high capacity streptavidin agarose resin, washed, eluted
and subjected to LC-MS/MS for quantification. The procedure of ABPP and
measurement of secretome are detailed in Supplementary Method.
Imaging- and cell-based drug screening assay. Parental or IR cells (SP49 and
SP49-IR) were seeded in multi-well plates with previously established human-
derived stroma and collagen-a to a total volume of 8 ml. Each well was filled with
80ml of RPMI 1640 media supplemented with FBS (10%, heat inactivated),
antibiotics (1% penicillin/streptomycin) and left overnight for adhesion of stroma.
The next day drugs were added using a robotic plate handler, so that every
drug was tested at five concentrations (1:3 serial dilution) and two replicates.
Negative controls (no drug) were included, as well as positive controls for each
drug (cell line MM1.S at highest drug concentration). Plates were placed in a
motorized stage microscope (EVOS Auto FL, Life Technologies) equipped with an
incubator and maintained at 5% CO2 and 37 C. Each well was imaged every
30min for a total duration of 4 days (96 h). To determine changes in viability of
each well longitudinally across the 96 h interval, a digital image analysis algorithm
was used. In summary, this algorithm computes differences in sequential
images and identifies as live cells those with continuous membrane deformations
(pseudo-coloured in green) resulting from the interaction with the surrounding
matrix. These interactions cease upon cell death. By applying this operation to all
192 images acquired for each well, it is possible to quantify non-destructively and
without the need of separation between stroma and lymphoma cells, the effect of
drugs as a function of concentration and exposure. Changes in viability are
quantified by area under curve (AUC)28.
Sanger sequencing. Genomic DNAs were isolated from MCL cell lines using
the DNeasy blood and tissue kit (Qiagen). The following primers were used to
amplify the DNA regions encoding either the wild type or the C481S and
R665W mutations in BTK and PLCG2 respectively (Life Technology)
BTK: 50-AGTTGTATGGCGTCTGCACCAA-30 (forward)
50-AGGTCTCGGTGAAGGAACTGCT-30 (reverse).
PLCG2: 50-GGTCCAAGGCTTTCAGAAACCCC-30 (forward)
50-GAAGGACAGGGTGTAGTCATTGGGG-30 (reverse).
DNAs were amplified with the Platinum Taq DNA polymerase (Life
Technology) and PCR products were purified with the QIAquick PCR purification
kit (Qiagen). Sanger sequencing was performed at the Institute of Biotechnology of
Cornell University.
Patient-derived xenograft model. Primary MCL cells were isolated from lymph
node of patients and injected into human bone chips and performed as previously
described30. For a more detailed description about generation and features of
PDX model and clinical characterization of IR patient used for PDX, see the
Supplementary Method. Cell assay, western blotting (uncropped scans of the
blots are also available in the Supplementary Information), mouse model and
statistical details are also provided in Supplementary Method.
Data availability. ABPP raw data are available via ProteomeXchange with
identifier PXD005734, Kinase peptide lists and intensity are in available in
Supplementary Data 1. Other data that support the findings of this study are
available from the authors on reasonable request; see author contributions for
specific data sets.
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